Latest Breaking News On - Corporate affairs brand strategy - Page 1 : comparemela.com

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

SOUTH SAN FRANCISCO, Calif., May 23, 2024 Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and autoimmune.

Christine cassianoCorporate affairs brand strategyAllogene therapeutics incAnnual oncology innovationSouth san franciscoForward looking statementsPrivate securities litigation reform actQuarterly reportAllogene therapeuticsInvestor contactChief corporate affairsBrand strategy

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesChristine cassianoCorporate affairs brand strategyProspectus departmentGoldman sachs coAllogene therapeutics incExchange commissionManagement teamAllogene boardExecutive managementGoldman sachsSouth san franciscoForward looking statementsPrivate securities litigation reform actAllogene therapeutics

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 Allogene Therapeutics, Inc. , a clinical-stage biotechnology.

Christine cassianoAllogene therapeutics incCorporate affairs brand strategyConference callWebcast scheduledSouth san franciscoForward looking statementsPrivate securities litigation reform actAnnual reportAllogene therapeuticsInvestor contactChief corporate affairsBrand strategy

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma ALLO-316 Illustrates Proof-of-Concept in RCC and.

United statesSouth san franciscoChristine cassianoZachary robertsResearch developmentCalifornia institute for regenerative medicineAllogene therapeutics incDrug administrationTechnology to optimize cart cell expansionTherapeutics developmentCorporate affairs brand strategyAmerican cancer societyOngoing phaseMetastatic renal cell carcinomaCell expansionCalifornia institute

Allogene Therapeutics Announces Q2 Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., April 09, 2024 Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and.

Christine cassianoAllogene therapeutics incCorporate affairs brand strategySecurities life sciences conferenceGoldman sachsGenuity horizonsOncology virtualLife sciences conferenceMarkets global healthcare conferenceAnnual healthcare conferenceSouth san franciscoForward looking statementsPrivate securities litigation reform actAnnual reportAllogene therapeuticsInvestor contact